Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.

about

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.

Item

http://www.wikidata.org/entity/Q54974100

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Targeted therapies in the mana ...... c cancer: a systematic review.

@en

Targeted therapies in the mana ...... c cancer: a systematic review.

@nl

type

Item

label

Targeted therapies in the mana ...... c cancer: a systematic review.

@en

Targeted therapies in the mana ...... c cancer: a systematic review.

@nl

prefLabel

Targeted therapies in the mana ...... c cancer: a systematic review.

@en

Targeted therapies in the mana ...... c cancer: a systematic review.

@nl

P1476

Targeted therapies in the mana ...... ic cancer: a systematic review

@en

P2093

Andrew V Biankin

http://www.w3.org/2001/XMLSchema#string

Anjali V Sheahan

http://www.w3.org/2001/XMLSchema#string

P2860

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

Cancer statistics, 2016

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotini

Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.

P304

21613-21627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25085

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Levon M Khachigian

Christopher R Parish

P577

2018-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29765563

http://www.w3.org/2001/XMLSchema#string

P932

5940404

http://www.w3.org/2001/XMLSchema#string